色谱

• • 上一篇    下一篇

制备高效液相色谱用于莫匹罗星杂质的纯化

程松波, 张淇, 傅青, 金郁*   

  1. 华东理工大学药学院, 上海 200237
  • 收稿日期:2026-02-05
  • 通讯作者: *Tel:021-64250633,E-mail:jiny@ecust.edu.cn.
  • 作者简介:程松波. E-mail:Y30231140@mail.ecust.edu.cn.在读硕士研究生.

Purification of mupirocin impurities based on preparative high performance liquid chromatography

CHENG Songbo, ZHANG Qi, FU Qing, JIN Yu*   

  1. School of pharmacy, East China University of Science and Technology, shanghai 200237, China
  • Received:2026-02-05

摘要: 莫匹罗星作为一种由荧光假单胞菌(Pseudomonas fluorescens)发酵产生的广谱抗生素,在临床皮肤细菌感染治疗领域占据重要地位。杂质研究是药品质量控制的重要内容,本研究以莫匹罗星杂质的制备为目标,建立了基于制备高效液相色谱(prep-HPLC)技术的多步纯化法,制备得到莫匹罗星杂质B、D和E。实验首先采用C18固定相对莫匹罗星结晶母液进行粗分离,降低样品复杂程度。经过粗分离以后,杂质B的纯度提高到87.2%,再一次的纯化只需要在C18固定相上调整洗脱方法,即可获得高纯度的杂质B。但是杂质D和E是同分异构体,在分析水平为未完全分离的两个峰,且含量相当,制备难度较大,所以仍需再结合C18和X4填料的互补性,以C18实现其余色谱峰的去除和两者相对比例的改变,再使用X4固定相调整分离选择性和保证在大上样量下的峰形,才能成功得到莫匹罗星杂质D和E。最终得到的杂质B、D和E的色谱纯度分别为98.7%、96.6%和99.6%。该方法可为莫匹罗星杂质制备提供方法学参考,有助于莫匹罗星杂质谱的研究。

关键词: 莫匹罗星, 杂质, 制备高效液相色谱, 纯化, 结构表征

Abstract: Mupirocin, a broad-spectrum antibiotic produced by the fermentation of Pseudomonas fluorescens, plays an important role in the clinical treatment of bacterial skin infections. Mupirocin production relies on microbial fermentation, a highly complex bioprocess. Critical parameters such as fermentation temperature, pH, and cultivation duration directly influence metabolic pathways. The final product is not a single compound but a multi-component mixture that contains both the active pharmaceutical ingredient and associated fermentation by-products. Additionally, it includes degradation products formed during downstream processing or storage. This study established a multi-step purification method utilizing preparative high performance liquid chromatography (prep-HPLC) for the isolation of mupirocin-related impurities B, D, and E. The HPLC analysis was performed on a Unitary C8 column (250 mm×4.6 mm, 5 μm) using a mobile phase consisting of A (7.7 g/L ammonium acetate solution adjusted to pH 5.7) and B (tetrahydrofuran). The gradient conditions were applied: 0-6 min, 25%B; 6-35 min, 25%B-30%B; 35-55 min, 30%B; 55-55.01 min, 30%B-25%B; 55. 01-60 min, 25%B. The flow rate was set at 1.0 mL/min and the column temperature was maintained at 35 ℃. First, the post-crystallization mother liquor was analyzed to confirm the presence of the target impurities. The mobile phase employed for purification consisted of A (0.1% formic acid aqueous solution) and B (acetonitrile). To reduce sample complexity, the post-crystallization mother liquor was diluted with 50% acetonitrile aqueous solution to a final mass concentration of approximately 400 mg/mL. A preparative separation was performed using a C18 column (250 mm×100 mm, 10 μm). The following gradient conditions were applied: 0-40 min, 25%B-50%B; 40-50 min, 50%B, at a flow rate of 280 mL/min and an injection volume of 90 mL. Fractions 1 to 8 (Fr.1-8) were collected, desalted, and rotary-evaporated. The resulting residues were then redissolved in 50% acetonitrile aqueous solution to a final mass concentration of approximately 100 mg/mL. Subsequent analysis revealed that Fr.8, which contained impurity B, exhibited high purity with minimal interference from other impurities. Further purification was performed using a C18 column (250 mm×50 mm, 10 μm). The following gradient conditions were applied: 0-25 min, 35%B-50% B; 25-35 min, 50%B, at a flow rate of 70 mL/min and an injection volume of 10 mL. This process yielded highly purified fractions of impurity B. Impurities D and E were detected in Fr.5. To remove interfering components eluting before and after the target impurity peaks, initial purification was performed using a C18 column (250 mm×50 mm, 10 μm). The gradient conditions were applied: 0-35 min, 35%B-50%B; 35-60 min, 50%B, at a flow rate of 70 mL/min and an injection volume of 10 mL. Fr.5-1 and Fr.5-2 were collected. Subsequent analysis revealed that the X4 stationary phase provided better resolution of impurities D and E compared with the C18 phase (Rs=1.63 vs. 1.12). Therefore, Fr.5-1 and Fr.5-2 were further purified using an X4 column (250 mm×50 mm, 10 μm). The gradient conditions were applied: 0-50 min, 25%B-35%B, at a flow rate of 70 mL/min and an injection volume of 5 mL, yielding purified fractions of impurities D and E. Desalting was performed on a C18 column using mobile phase A (H2O) and B (acetonitrile). Prior to loading, the fractions were diluted twofold with water. After sample loading, desalting was carried out with 10%B for 20 min, followed by 100%B until complete elution of the sample. The detection wavelength was set at 240 nm. The collected fractions were concentrated to dryness by rotary evaporation at 25 ℃, and the purified impurities were further lyophilized. Based on the orthogonality of the separation mechanisms of the C18 and X4 stationary phases, impurities B, D, and E were successfully isolated with chromatographic purities of 98.7%, 96.64% and 99.6%. Their weights of them were 963, 629.2 and 1096.4 mg, respectively. These impurities meet the purity requirements for drug impurity reference standards and can serve as standard substances for mupirocin quality control. The developed method exhibits high sample loading capacity, separation efficiency, and stability, providing a valuable methodological reference for the preparation of mupirocin-related substances and facilitating the establishment of its impurity profile.

Key words: Mupirocin, Impurities, Preparative high-performance liquid chromatography, Purification, Structural characterization

中图分类号: